The relationship between estrogen and ovarian cancer is obscure. It is known that there are both estrogen and progesterone receptors present in many epithelial ovarian tumours. Unfortunately, the effects of exogenous hormones on these receptors are not well defined. There is no convincing evidence that estrogen has either the potential to promote recurrence or to decrease the time to recurrence.
In the absence of scientific evidence to the contrary, it is not necessary to withhold estrogen replacement therapy from any symptomatic woman with ovarian malignancy regardless of risk category.
Recommendations:
- In the absence of a uterus and when the cancer is not endometriosis-associated, estrogen alone can be considered.
- Estrogen plus progesterone or estrogen with bazedoxifine [63] are both suitable options in o patients with a retained uterus.
o Endometriosis-associated cancers with residual endometriosis even if the uterus has been removed.
63. Raina PM, Patel P, Parmar M. Bazedoxifene. [Updated 2024 Feb 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK585122/
